 Interleukin-1
"Interleukin-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.
| Descriptor ID |
D007375
|
| MeSH Number(s) |
D12.644.276.374.465.010 D12.644.276.374.500.400 D12.776.467.374.465.010 D12.776.467.374.500.400 D23.529.374.465.131 D23.529.374.500.400
|
| Concept/Terms |
Interleukin-1- Interleukin-1
- Interleukin 1
- IL-1
- T Helper Factor
- Lymphocyte-Activating Factor
- Lymphocyte Activating Factor
- Macrophage Cell Factor
- Epidermal Cell Derived Thymocyte-Activating Factor
- Epidermal Cell Derived Thymocyte Activating Factor
- Interleukin I
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-1".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-1".
This graph shows the total number of publications written about "Interleukin-1" by people in this website by year, and whether "Interleukin-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 18 | 7 | 25 | | 1993 | 20 | 10 | 30 | | 1994 | 24 | 5 | 29 | | 1995 | 15 | 8 | 23 | | 1996 | 12 | 5 | 17 | | 1997 | 12 | 4 | 16 | | 1998 | 13 | 1 | 14 | | 1999 | 11 | 9 | 20 | | 2000 | 14 | 5 | 19 | | 2001 | 10 | 9 | 19 | | 2002 | 1 | 10 | 11 | | 2003 | 8 | 6 | 14 | | 2004 | 13 | 7 | 20 | | 2005 | 5 | 7 | 12 | | 2006 | 6 | 3 | 9 | | 2007 | 2 | 1 | 3 | | 2008 | 1 | 0 | 1 | | 2009 | 3 | 2 | 5 | | 2010 | 4 | 4 | 8 | | 2011 | 4 | 1 | 5 | | 2012 | 1 | 4 | 5 | | 2013 | 4 | 2 | 6 | | 2014 | 6 | 2 | 8 | | 2015 | 9 | 2 | 11 | | 2016 | 6 | 0 | 6 | | 2017 | 8 | 1 | 9 | | 2018 | 2 | 2 | 4 | | 2019 | 10 | 2 | 12 | | 2020 | 3 | 1 | 4 | | 2021 | 6 | 2 | 8 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-1" by people in Profiles.
-
de Graaf DM, Wang RX, Amo-Aparicio J, Lee JS, Dowdell AS, Tengesdal IW, Marchetti C, Colgan SP, Joosten LAB, Dinarello CA. IL-38 Gene Deletion Worsens Murine Colitis. Front Immunol. 2022; 13:840719.
-
Javan H, Li L, Schaaf CL, Lee YS, Salama ME, Dinarello CA, Selzman CH. Interleukin-1 Receptor Antagonism Abrogates Acute Pressure Overload-Induced Murine Heart Failure. Ann Thorac Surg. 2022 07; 114(1):98-107.
-
van Deuren RC, Arts P, Cavalli G, Jaeger M, Steehouwer M, van de Vorst M, Gilissen C, Joosten LAB, Dinarello CA, Mhlanga MM, Kumar V, Netea MG, van de Veerdonk FL, Hoischen A. Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. Genome Med. 2021 05 25; 13(1):94.
-
Kouwenberg M, Pulskens WPC, Diepeveen L, Bakker-van Bebber M, Dinarello CA, Netea MG, Hilbrands LB, van der Vlag J. Reduced CXCL1 production by endogenous IL-37 expressing dendritic cells does not affect T cell activation. PLoS One. 2021; 16(5):e0251809.
-
Cavalli G, Tengesdal IW, Gresnigt M, Nemkov T, Arts RJW, Domínguez-Andrés J, Molteni R, Stefanoni D, Cantoni E, Cassina L, Giugliano S, Schraa K, Mills TS, Pietras EM, Eisenmensser EZ, Dagna L, Boletta A, D'Alessandro A, Joosten LAB, Netea MG, Dinarello CA. The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. Cell Rep. 2021 04 06; 35(1):108955.
-
Mountford S, Effenberger M, Noll-Puchta H, Griessmair L, Ringleb A, Haas S, Denk G, Reiter FP, Mayr D, Dinarello CA, Tilg H, Bufler P. Modulation of Liver Inflammation and Fibrosis by Interleukin-37. Front Immunol. 2021; 12:603649.
-
de Graaf DM, Teufel LU, van de Veerdonk FL, Joosten LAB, Netea MG, Dinarello CA, Arts RJW. IL-38 prevents induction of trained immunity by inhibition of mTOR signaling. J Leukoc Biol. 2021 11; 110(5):907-915.
-
Hamilton JAG, Lee MY, Hunter R, Ank RS, Story JY, Talekar G, Sisroe T, Ballak DB, Fedanov A, Porter CC, Eisenmesser EZ, Dinarello CA, Raikar SS, DeGregori J, Henry CJ. Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Aging Cell. 2021 02; 20(2):e13309.
-
Sánchez-Fernández A, Zandee S, Amo-Aparicio J, Charabati M, Prat A, Garlanda C, Eisenmesser EZ, Dinarello CA, López-Vales R. IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. Theranostics. 2021; 11(1):1-13.
-
Rønholt K, Nielsen AL, Johansen C, Vestergaard C, Fauerbye A, López-Vales R, Dinarello CA, Iversen L. IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. Immunohorizons. 2020 11 25; 4(11):754-761.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|